BioNTech's stock dropped significantly following a disappointing trial outcome.
BioNTech SE (BNTX) saw a 7.0% decline after its mRNA cancer trial missed the progression-free survival (PFS) goal. This raises concerns about the company’s future and the strength of its bullish outlook. The last closing price for BioNTech was US$89.31, reflecting a 7.13% drop for the day. Over the past week, the stock has fallen by 7.02%, and it is down 7.98% over the last month, contributing to a year-to-date decline of 7.94%.
Investor takeaway: Keep an eye on developments in BioNTech's oncology pipeline following this trial setback.
Advertisement
BioNTech SE
BNTX.US
BNTX.US
BioNTech SE
WealthAwesomeMarket cap
$22.36B
52W high
$124.00
52W low
$79.52
1W change
-7.02%
Beta
1.25
Analyst Price Targets
Based on 21 analysts covering BNTX · as of Oct 14, 2026
Wall Street analysts forecast BNTX stock price to rise 30.6% over the next 12 months.
Consensus
Buy4.24 / 5.00
Avg. Target
C$116.28
+30.6% Upside
Previously C$116.21 on Oct 12, 2026
Current Price
C$89.01
Last close
Analyst Breakdown (21 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BNTX's historical volatility
30-Day Vol
39.1%
Annualized
90-Day Vol
48.8%
Annualized
Trend (90d)
-14.6%
Annualized drift
90d Mean
C$84.49
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$87.48 | C$76.44 – C$100.10 |
| 60 trading days | C$85.97 | C$71.05 – C$104.02 |
| 90 trading days | C$84.49 | C$66.89 – C$106.70 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Bull case
Analysts have set an average target price of US$116.28 for BioNTech, suggesting a potential upside of 30.2% from the current price.
Bear case
The company currently has a profit margin of -63.6%, indicating ongoing financial struggles, along with a negative EPS of -7.83.
BioNTech's Stock Reaction
After the announcement that BioNTech's mRNA cancer trial did not meet its PFS goal, the stock price dropped to US$89.31, marking a 7.0% decrease for the day. This decline is part of a larger trend, with the stock down about 7.98% over the past month and 7.94% year-to-date. The stock's performance also reflects its position within a 52-week range of US$79.52 to US$124.00, currently sitting at about 22% of this range.
Advertisement
Trading Volume Surges
On this day, BioNTech's trading volume reached 322,471 shares, significantly higher than the 20-day average volume of 901,081 shares. This represents a volume that is 2.12 times the average, indicating increased investor activity in response to the trial results. The surge in volume suggests that investors are reacting strongly to the news, potentially reassessing their positions as they evaluate the implications of the trial outcome on BioNTech's future.
Future Outlook and Considerations
With the recent trial setback, investors will be eager to see how this impacts BioNTech's oncology pipeline and overall strategy. Analysts maintain an average target price of US$116.28, indicating a potential upside of 30.2% from the current price. However, the company's negative profit margins (-63.6%) and a negative return on equity (ROE) of -9.3% highlight ongoing financial challenges. The outlook for BioNTech remains uncertain as stakeholders await further updates regarding its oncology developments.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
